JCRB4057 GTO
Cell information
Important Notice(s)Cultivation and Freezing of GTO （JCRB4057)
Cell type：general cells (View Pricing Information)
| JCRB No. | JCRB4057 | Cell Name | GTO |
|---|---|---|---|
| Profile | Primary effusion lymphoma (PEL) cell line derived from a human immunodeficiency virus-1 (HIV-1)-infected patient. (HHV-8 positive, EBV negative, CD4 positive.) | Other Name | |
| Animal | human | Strain | |
| Genus | Homo | Species | sapiens |
| Sex | M | Age | 39-year-old |
| Identity | not done | Tissue for Primary Cancer | hemo-lymphocytic |
| Case history | HIV-1 carrier, Primary effusion lymphoma (PEL) | Metastasis | |
| Tissue Metastasized | Genetics | ||
| Life Span | infinite | Crisis PDL | |
| Morphology | lymphocyte-like | Character | |
| Classify | tumor | Established by | Seiji OKADA |
| Registered by | Regulation for Distribution | ||
| Comment | Year | ||
| Medium | RPMI 1640 supplemented with 10 % FBS. | Methods for Passages | dilution |
| Cell Number on Passage | Race | Japanese | |
| CO2 Conc. | 5% | Tissue Sampling | pericardial fluid (心嚢液) |
| Tissue Type |
| Detection of virus genome fragment by Real-time PCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Detected DNA Virus | tested | Detected RNA Virus | tested | ||||||
| CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
| EBV | - | HBV | - | HIV-1 | - | HTLV-2 | - | ||
| HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
| HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
| BKV | - | HIV-1 | - | ||||||
| JCV | - | HIV-2 | - | ||||||
| ADV | - | HPV18 | - | ||||||
| Notes | HHV-8(+) | ||||||||
| Reference | |
|---|---|
| Pubmed id:23605439 | Establishment of a CD4-positive cell line from an AIDS-related primary effusion lymphoma. Goto H,Kojima Y,Nagai H,Okada S Int J Hematol. 2013 May;97(5):624-33 |
LOT Information
Viability/Growth rate/Cell number are represented as actual values measured at lot presentation in JCRB, but are not guaranteed values. Additionally, the doubling time is a rough value measured during passages.| Cell No. | JCRB4057 | Cell Name | GTO |
|---|---|---|---|
| LOT No. | 02102025 | Lot Specification | distribution |
| Medium | RPMI1640(GIBCO Cat #11875-093) with 10% heat inactivated fetal bovine serum (Nichirei Cat. # 174112, Lot 20M00K) | Temperature | 37 C |
| Cell Density at Seeding | 0.9-1.4x10^5 cells/mL | Methods for Passages | Dilution (split ratio=1/10-20), twice per week |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 3.8x10^6 |
| Viability at cell freezing (%) | 99.50 | Antibiotics Used | free |
| Passage Number | p6* | PDL | NT |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NT |
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | D5S818:10,14 D13S317:11,12 D7S820:9,11 D16S539:9 VWA:18 TH01:7 AM:X TPOX:11 CSF1PO:10,12 |
| Adhesion | No | Exoteric Gene | NT |
| Medium for Freezing | CELLBANKER1((Nihon Zenyaku Industries) | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | 24.7 | Additional information | This cell line was infected with HHV-8, but not with EBV, clonal B cell proliferation |
| Cell No. | JCRB4057 | Cell Name | GTO |
|---|---|---|---|
| LOT No. | 03102025 | Lot Specification | distribution |
| Medium | RPMI1640(GIBCO Cat #11875-093) with 10% heat inactivated fetal bovine serum (Nichirei Cat. # 174112, Lot 20M00K) | Temperature | 37 C |
| Cell Density at Seeding | 0.5-1.3x10^5 cells/mL | Methods for Passages | Dilution (split ratio=1/10-20), twice per week |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 4.0x10^6 |
| Viability at cell freezing (%) | 97.00 | Antibiotics Used | free |
| Passage Number | p9* | PDL | NT |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NT |
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | D5S818:10,14 D13S317:11,12 D7S820:9,11 D16S539:9 VWA:18 TH01:7 AM:X TPOX:11 CSF1PO:10,12 |
| Adhesion | No | Exoteric Gene | NT |
| Medium for Freezing | DMSO 20% + FBS 40% +RPMI1640 50% | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | 45.9 | Additional information | IF cells are cryopreserved at low cell density, they can be thawed and cultured with good viability. |
| Cell No. | JCRB4057 | Cell Name | GTO |
|---|---|---|---|
| LOT No. | 03132025 | Lot Specification | distribution |
| Medium | RPMI1640(GIBCO Cat #11875-093) with 10% heat inactivated fetal bovine serum (Nichirei Cat. # 174112, Lot 20M00K) | Temperature | 37 C |
| Cell Density at Seeding | 0.5-1.3x10^5 cells/mL | Methods for Passages | Dilution (split ratio=1/10-20), twice per week |
| Doubling Time | NT | Cell Number in Vial (cells/1ml) | 3.1x10^6 |
| Viability at cell freezing (%) | 97.20 | Antibiotics Used | free |
| Passage Number | p10* | PDL | NT |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NT |
| Chromosome Mode | NT | Chromosome Information | NT |
| Surface Antigen | NT | DNA Profile (STR) | D5S818:10,14 D13S317:12 D7S820:9,11 D16S539:9 VWA:18 TH01:7 AM:X TPOX:11 CSF1PO:10,12 |
| Adhesion | No | Exoteric Gene | NT |
| Medium for Freezing | BAMBANKER (LYMPHOTEC Inc., CS-02-001, NIPPON Genetics Co., LTD) | CO2 Conc. | 5% |
| Viability immediately after thawing (%) | 53.1 | Additional information | IF cells are cryopreserved at low cell density, they can be thawed and cultured with good viability. |